Gene expression studies identify a new miR-27b-mediated regulatory pathway that targets MAIP1 and leads to hepatic lipid accumulation in cultured human and mouse hepatic cells suggesting a potential role for MAIP1 as a therapeutic target for NAFLD. Here, MAIP1 is linked to metabolic dysfunction-associated steatotic liver disease.